Switch theme
Sign up to access all valuation multiples
AprilBio Co Ltd is a bio company is developing biologis. It owns long acting protein medicine platform technology utilizing human FAB antobody parts that makes unusual combination to serum akbumin and EX 12 helper phase antibody library technology.
2013
26
LTM Revenue $17.0M
LTM EBITDA $8.7M
$208M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AprilBio has a last 12-month revenue (LTM) of $17.0M and a last 12-month EBITDA of $8.7M.
In the most recent fiscal year, AprilBio achieved revenue of $20.0M and an EBITDA of $16.1M.
AprilBio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AprilBio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $17.0M | XXX | $20.0M | XXX | XXX | XXX |
| Gross Profit | $17.0M | XXX | $20.0M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | $8.7M | XXX | $16.1M | XXX | XXX | XXX |
| EBITDA Margin | 51% | XXX | 80% | XXX | XXX | XXX |
| EBIT | $8.4M | XXX | $12.3M | XXX | XXX | XXX |
| EBIT Margin | 50% | XXX | 61% | XXX | XXX | XXX |
| Net Profit | $11.4M | XXX | $14.5M | XXX | XXX | XXX |
| Net Margin | 67% | XXX | 73% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AprilBio's stock price is KRW 17180 (or $12).
AprilBio has current market cap of KRW 377B (or $274M), and EV of KRW 287B (or $208M).
See AprilBio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $208M | $274M | XXX | XXX | XXX | XXX | $0.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AprilBio has market cap of $274M and EV of $208M.
AprilBio's trades at 10.4x EV/Revenue multiple, and 13.0x EV/EBITDA.
Equity research analysts estimate AprilBio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AprilBio has a P/E ratio of 24.1x.
See valuation multiples for AprilBio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $274M | XXX | $274M | XXX | XXX | XXX |
| EV (current) | $208M | XXX | $208M | XXX | XXX | XXX |
| EV/Revenue | 12.2x | XXX | 10.4x | XXX | XXX | XXX |
| EV/EBITDA | 23.8x | XXX | 13.0x | XXX | XXX | XXX |
| EV/EBIT | 24.7x | XXX | 17.0x | XXX | XXX | XXX |
| EV/Gross Profit | 12.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.1x | XXX | 18.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 13.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAprilBio's last 12 month revenue growth is 1%
AprilBio's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.3M for the same period.
AprilBio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AprilBio's rule of X is 53% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AprilBio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 51% | XXX | 80% | XXX | XXX | XXX |
| EBITDA Growth | -14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | 81% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 53% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AprilBio acquired XXX companies to date.
Last acquisition by AprilBio was XXXXXXXX, XXXXX XXXXX XXXXXX . AprilBio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AprilBio founded? | AprilBio was founded in 2013. |
| Where is AprilBio headquartered? | AprilBio is headquartered in South Korea. |
| How many employees does AprilBio have? | As of today, AprilBio has 26 employees. |
| Is AprilBio publicy listed? | Yes, AprilBio is a public company listed on KRX. |
| What is the stock symbol of AprilBio? | AprilBio trades under 397030 ticker. |
| When did AprilBio go public? | AprilBio went public in 2022. |
| Who are competitors of AprilBio? | Similar companies to AprilBio include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AprilBio? | AprilBio's current market cap is $274M |
| What is the current revenue of AprilBio? | AprilBio's last 12 months revenue is $17.0M. |
| What is the current revenue growth of AprilBio? | AprilBio revenue growth (NTM/LTM) is 1%. |
| What is the current EV/Revenue multiple of AprilBio? | Current revenue multiple of AprilBio is 12.2x. |
| Is AprilBio profitable? | Yes, AprilBio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AprilBio? | AprilBio's last 12 months EBITDA is $8.7M. |
| What is AprilBio's EBITDA margin? | AprilBio's last 12 months EBITDA margin is 51%. |
| What is the current EV/EBITDA multiple of AprilBio? | Current EBITDA multiple of AprilBio is 23.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
